BiotechTube

Eteplirsen

Phase 3Active
2 views this week 0 watching💤 Quiet💊Featured in Rare Disease Pipeline Watch
Interest: 38/100
38
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Muscular Dystrophy, Duchenne

Conditions

Muscular Dystrophy, Duchenne

Trial Timeline

Jul 13, 2020 → Oct 31, 2026

NCT ID
NCT03992430

About Eteplirsen

Eteplirsen is a phase 3 stage product being developed by Sarepta Therapeutics for Muscular Dystrophy, Duchenne. The current trial status is active. This product is registered under clinical trial identifier NCT03992430. Target conditions include Muscular Dystrophy, Duchenne.

What happened to similar drugs?

14 of 20 similar drugs in Muscular Dystrophy, Duchenne were approved

Approved (14) Terminated (2) Active (5)
❌Tadalafil + PlaceboEli LillyPhase 3
🔄Viltolarsen + PlaceboNippon ShinyakuPhase 3
🔄ViltolarsenNippon ShinyakuPhase 3
✅GoserelinAstraZenecaApproved
✅Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Sugammadex 16 mg/kg + Neostigmine + Glycopyrrolate + Rocuronium + VecuroniumMerckApproved
✅Deep neuromuscular block + Moderate neuromuscular blockMerckApproved
✅Sugammadex + RocuroniumMerckApproved

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
0
Community
0

Clinical Trials (6)

NCT IDPhaseStatus
NCT03992430Phase 3Active
NCT03985878Phase 2Terminated
NCT03218995Phase 2Completed
NCT02420379Phase 2Completed
NCT02255552Phase 3Completed
NCT02286947Phase 2Completed

Competing Products

20 competing products in Muscular Dystrophy, Duchenne

See all competitors
ProductCompanyStageHype Score
Phase 1, SQY51 + Phase 2a, SQY51 (cohort 1) + Phase 2a, SQY51 (cohort 2) + Phase 2a, SQY51 (cohort 3)BiotrialPhase 1/2
29
ENTR-601-44 + ENTR-601-44 - matching placeboEntrada TherapeuticsPhase 1/2
29
ENTR-601-45 + ENTR-601-45 - matching placeboEntrada TherapeuticsPhase 1/2
29
Tadalafil + PlaceboEli LillyPhase 3
32
DS-5141bDaiichi SankyoPhase 2
39
DS-5141bDaiichi SankyoPhase 1/2
32
Bocidelpar + PlaceboAstellas PharmaPhase 1
21
scAAV9.U7.ACCAAstellas PharmaPhase 1/2
32
Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mgAstellas PharmaPhase 2
35
LY2495655 + PlaceboEli LillyPhase 2
35
HRS-9190; under Inhalational Anesthesia + HRS-9190; under Intravenous Anesthesia + Cisatracurium (under Inhalational Anesthesia). + Cisatracurium (under Intravenous Anesthesia)Jiangsu Hengrui MedicinePhase 2
42
HRS-9190 + HRS-9190 + HRS-9190 + HRS-9190 + Rocuronium + RocuroniumJiangsu Hengrui MedicinePhase 2
42
HRS-9190 + HRS-9190 + HRS-9190Jiangsu Hengrui MedicinePhase 2
35
NS-065/NCNP-01Nippon ShinyakuPhase 2
35
Viltolarsen + PlaceboNippon ShinyakuPhase 3
40
ViltolarsenNippon ShinyakuPhase 2
35
NS-089/NCNP-02 + NS-089/NCNP-02Nippon ShinyakuPhase 2
39
NS-065/NCNP-01Nippon ShinyakuPhase 1
29
NS-050/NCNP-03 + PlaceboNippon ShinyakuPhase 1/2
39
NS-089/NCNP-02Nippon ShinyakuPhase 2
42